Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karen Augustine-Rauch

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Frontiers in Medicine|September 12, 2025
NFE2 and PF4 as biomarkers for BET inhibition-induced thrombocytopenia in preclinical and clinical studiesCindy Zhang, Ke Xu, Faye Wang, et al.
Iscience|March 5, 2021
TGFβ2 and TGFβ3 mediate appropriate context-dependent phenotype of rat valvular interstitial cellsFaye Wang, Cindy Zhang, Jae Kwagh, et al.
Birth Defects Research. Part B, Developmental and Reproductive Toxicology|August 15, 2008
State of the art in developmental toxicity screening methods and a way forward: a meeting report addressing embryonic stem cells, whole embryo culture, and zebrafishRobert Chapin, Karen Augustine-Rauch, Bruce Beyer, et al.
Journal of Medicinal Chemistry|October 27, 2021
Long-Acting Tumor-Activated Prodrug of a TGFβR InhibitorYong Zhang, Karen E Parrish, David R Tortolani, et al.
ACS Medicinal Chemistry Letters|November 16, 2018
Discovery of 4-Azaindole Inhibitors of TGFβRI as Immuno-oncology AgentsYong Zhang, Yufen Zhao, Andrew J Tebben, et al.
ACS Medicinal Chemistry Letters|February 20, 2020
Discovery of BMS-986260, a Potent, Selective, and Orally Bioavailable TGFβR1 Inhibitor as an Immuno-oncology AgentUpender Velaparthi, Chetan Padmakar Darne, Jayakumar Warrier, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Frontiers in Medicine|September 12, 2025
NFE2 and PF4 as biomarkers for BET inhibition-induced thrombocytopenia in preclinical and clinical studiesCindy Zhang, Ke Xu, Faye Wang, et al.
Iscience|March 5, 2021
TGFβ2 and TGFβ3 mediate appropriate context-dependent phenotype of rat valvular interstitial cellsFaye Wang, Cindy Zhang, Jae Kwagh, et al.
Birth Defects Research. Part B, Developmental and Reproductive Toxicology|August 15, 2008
State of the art in developmental toxicity screening methods and a way forward: a meeting report addressing embryonic stem cells, whole embryo culture, and zebrafishRobert Chapin, Karen Augustine-Rauch, Bruce Beyer, et al.
Journal of Medicinal Chemistry|October 27, 2021
Long-Acting Tumor-Activated Prodrug of a TGFβR InhibitorYong Zhang, Karen E Parrish, David R Tortolani, et al.
ACS Medicinal Chemistry Letters|November 16, 2018
Discovery of 4-Azaindole Inhibitors of TGFβRI as Immuno-oncology AgentsYong Zhang, Yufen Zhao, Andrew J Tebben, et al.
ACS Medicinal Chemistry Letters|February 20, 2020
Discovery of BMS-986260, a Potent, Selective, and Orally Bioavailable TGFβR1 Inhibitor as an Immuno-oncology AgentUpender Velaparthi, Chetan Padmakar Darne, Jayakumar Warrier, et al.
Pageof 2